Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...